Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of nalbuphine ER for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease

Next Previous
Trial Profile

A phase 2 study of nalbuphine ER for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions

Most Recent Events

  • 13 Jun 2019 According to a Trevi Therapeutics media release, based on feedback from the Food and Drug Administration (FDA) in a pre-IND meeting earlier this year, Trevi plans to submit an IND in preparation of this study which is expected to commence in the second half of 2019.
  • 12 Apr 2019 New trial record
  • 04 Apr 2019 According to a Trevi Therapeutics media release, the company is planning to initiate this study in 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top